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Type 2 diabetes can be prevented by adoption of a 
healthy diet and lifestyle. However, many people 
have diﬃ  culties complying with dietary and lifestyle 
changes, so the quest for more convenient ways to 
reduce diabetes risk continues. Vitamin D has been the 
focus of much interest in this regard.1
Epidemiological studies in human beings con-
sistently show that low blood concentrations of 
25-hydroxyvitamin D (25[OH]D, a marker of vitamin D 
status) are associated with an increased risk of type 2 
diabetes.2 These studies, however, cannot distinguish 
causation from association because of possible un-
controlled confounding and reverse causation. 
In The Lancet Diabetes & Endocrinology, Zheng Ye 
and colleagues3 make an important contribution by 
reporting the results of a mendelian randomisation 
study, which makes use of the interindividual variability 
in circulating 25(OH)D concentrations caused by 
common genetic variants. Because allocation of genetic 
variants at conception is independent of behavioural 
and environmental factors, their associations with 
disease are less likely to be aﬀ ected by confounding or 
reverse causation.4,5 
On the basis of the expression of four genetic variants 
that aﬀ ect plasma 25(OH)D concentrations (single 
nucleotide polymorphisms of DHCR7, CYP2R1, DBP 
[also known as GC], and CYP24A1), Ye and colleagues 
report that for each 25 nmol/L reduction in genetically 
determined 25(OH)D concentration, the odds ratio for 
type 2 diabetes was 1·01 (95% CI 0·75–1·36; p=0·94). 
This null result is in notable contrast to the association 
noted in observational studies: in their study, Ye 
and colleagues also meta-analysed 22 prospective 
observational studies and report a pooled relative 
risk of 1·21 (95% CI 1·16–1·27; p=7·3 × 10¹⁹). Taken 
together, these ﬁ ndings suggest that the inverse 
association for 25(OH)D concentration and type 2 
diabetes is not causal.
Ye and colleagues’ study is impressive in many 
ways. First and foremost is its sample size, with 
104 488 people included in the mendelian 
randomisation analysis. Second, the null result with 
respect to risk of type 2 diabetes was also seen for four 
glycaemic traits, which strengthens the credibility of 
the ﬁ ndings. Third, the authors updated their earlier 
meta-analysis of conventional epidemiological studies2 
by adding 11 more studies.
What accounts for the discrepancy between obser-
vational and mendelian randomisation studies? As 
the investigators state, uncontrolled confounding 
and reverse causation in observational studies are 
prime suspects. My group6 and others7 have shown 
that low circulating 25(OH)D concentrations are 
associated with general and central adiposity, physical 
inactivity, smoking, and low consumption of ﬁ sh and 
alcohol. Adiposity and physical inactivity are strong 
risk factors of type 2 diabetes. Physical activity is 
usually self-reported, but its accurate assessment 
is notoriously diﬃ  cult. So, the question is not 
whether there is measurement error, but how large 
it is. Adiposity is usually estimated with BMI, which 
does not include suﬃ  cient information about fat 
distribution. This issue could be important because 
low 25(OH)D concentration might be especially 
associated with central adiposity.6 However, the 
case of adiposity is special, because it might causally 
reduce circulating 25(OH)D concentration.8 Therefore, 
adjustment for adiposity could be inappropriate 
because it removes the mediating eﬀ ect of adiposity 
on 25(OH)D concentration. Finally, uncontrolled 
confounding might also occur by yet undiscovered 
metabolic processes that both contribute to type 2 
diabetes and aﬀ ect 25(OH)D concentration.
It is diﬃ  cult to address reverse causation in 
prospective observational studies. One method is to 
lag the statistical analysis by omitting cases that occur 
early during follow-up: attenuation of the association 
suggests reverse causation is possible. A better method 
is to repeatedly measure 25(OH)D concentration 
during follow-up to assess any variation in association 
over time. However, many studies do not include such 
analyses. Another approach is to investigate potential 
mechanisms of reverse causation. Reduced 25(OH)D 
concentration could result from pathophysiological 
processes leading to type 2 diabetes, perhaps via liver 
dysfunction, as suggested up by Ye and colleagues.3 
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If so, then stratifying the analysis for parameters of 
liver function might be worthwhile. Whether genetic 
variants that aﬀ ect concentrations of liver enzymes9 
predict 25(OH)D concentration is also currently 
unknown.
Mendelian randomisation studies hinge upon some 
partly unveriﬁ able assumptions.4,5 For example, the 
genetic variants should exclusively aﬀ ect the variable in 
question, in this case 25(OH)D concentration, without 
directly aﬀ ecting other vitamin D metabolites or other 
biological risk factors of diabetes. This assumption 
might not hold for all of the genetic variants used by 
Ye and colleagues.2 Vitamin D-binding protein (DBP), 
for example, binds not only to 25(OH)D, but also 
to other vitamin D metabolites and to fatty acids,10 
and might also have anti-inﬂ ammatory properties 
independent of vitamin D.11 DHCR7 also aﬀ ects 
cholesterol metabolism, and CYP24A1 inactivates 
not only 25(OH)D, but also hormonally active 
vitamin D. Because of these possible pleiotropic 
eﬀ ects, the results of mendelian randomisation 
studies need careful interpretation, and long-term 
randomised trials of vitamin D supplementation, 
which are underway,1 remain important. The results of 
a meta-analysis12 of 35 short-term trials, however, do 
not oﬀ er much hope that vitamin D supplementation 
can be used to prevent type 2 diabetes. Together with 
Ye and colleagues’ study, the sky is becoming rather 
clouded for vitamin D in the context of preventing 
type 2 diabetes.
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 Does mortality risk vary among sulfonylureas?
The University Group Diabetes Program raised concern in 
1970 when it reported an increased risk of cardiovascular 
mortality in patients who received tolbutamide.1 It was 
this ﬁ nding that largely prompted the initiation of the 
UK Prospective Diabetes Study (UKPDS),2 the ﬁ ndings of 
which did not support the suggestion that sulfonylurea 
treatment was associated with an increased risk of 
cardiovascular death. However, sulfonylurea use has 
been controversial ever since and many retrospective 
studies have subsequently reported an increased risk of 
adverse cardiovascular outcomes, mortality, or both, 
with sulfonylurea treatment, speciﬁ cally when compared 
with metformin.
Sulfonylureas have historically been analysed as a drug 
class, despite the fact that there are vast diﬀ erences 
in pharmacological properties among the individual 
sulfonylureas: hypoglycaemic risk, sulfonylurea receptor 
(SUR) subtype speciﬁ city and aﬃ  nity, and the ability 
to abolish ischaemic preconditioning. Glibenclamide 
is the sulfonylurea most commonly associated with 
hypoglycaemia.3 Some sulfonylureas (gliclazide and 
glipizide) are speciﬁ c for the pancreatic SUR1 receptors, 
thereby principally stimulating insulin secretion. Other 
sulfonylureas (glimepiride and glibenclamide) are not 
pancreas speciﬁ c; these drugs agonise both the pancreatic 
SUR1 receptors and the SUR2 receptors found on cardiac 
